نتایج جستجو برای: braf mutation

تعداد نتایج: 295289  

Journal: :Anticancer research 2010
Vitali Sviatoha Edneia Tani Mehran Ghaderi Regina Kleina Lambert Skoog

BACKGROUND metastatic melanomas are incurable by systemic treatment and it is therefore of the highest concern to develop new therapeutic regimens. RAF kinases play a key role in the RAS-RAF-MAPK signalling pathway which mediates cellular response to growth signals. An inhibitor of the RAS-RAF-MAPK cascade, sorafenib, has shown promising therapeutic results in treatment of several types of meta...

2018
Louise Johnston Michael Power Philip Sloan Anna Long Angela Silmon Ben Chaffey Andrea Jane Lisgo Liam Little Ellen Vercauteren Torben Steiniche Tine Meyer John Simpson

AIMS Understanding the molecular mechanisms of underlying disease has led to a movement away from the one-drug-fits-all paradigm towards treatment tailored to the genetic profile of the patient. The Biocartis Idylla platform is a novel fully automated, real-time PCR-based in vitro diagnostic system. The Idylla NRAS-BRAF mutation test has been developed for the qualitative detection of mutations...

Journal: :Journal of the National Cancer Institute 2014
Christophe Rosty Elizabeth J Williamson Mark Clendenning Rhiannon J Walters Michael D Walsh Aung K Win Mark A Jenkins John L Hopper Ingrid Winship Melissa C Southey Graham G Giles Dallas R English Daniel D Buchanan

Lochhead et al. recently reported the combined prognostic role of BRAF V600E mutation and microsatellite instability (MSI) in 1253 colorectal cancer patients with a median follow-up of 8.2 years (1). In their stage-stratified multivariable analyses that included age, year of diagnosis, body mass index (BMI), tumor differentiation, and LINE-1 methylation as additional covariables, they found tha...

Journal: :Molecular cancer therapeutics 2015
Zhiyu Tang Xi Yuan Rong Du Shing-Hu Cheung Guoliang Zhang Jing Wei Yuan Zhao Yingcai Feng Hao Peng Yi Zhang Yunguang Du Xiaoxia Hu Wenfeng Gong Yong Liu Yajuan Gao Ye Liu Rui Hao Shengjian Li Shaohui Wang Jiafu Ji Lianhai Zhang Shuangxi Li David Sutton Min Wei Changyou Zhou Lai Wang Lusong Luo

Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAF(V600E) metastatic melanoma, their clinical efficacy in BRAF(V600E) colorectal cancer is far less impressive. Prior studies su...

2015
Hiroyuki Mochizuki Matthew Breen

Activating mutations of the BRAF gene lead to constitutive activation of the MAPK pathway. The characterization and discovery of BRAF mutations in a variety of human cancers has led to the development of specific inhibitors targeting the BRAF/MAPK pathway and dramatically changed clinical outcomes in BRAF-mutant melanoma patients. Recent discovery of BRAF mutation in canine cancers underscores ...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011
K L Nathanson A Martin R Letrero K P D'Andrea S O'Day J R Infante G S Falchook M Millward C M Curtis B Ma R C Gagnon P F Lebowitz G V Long R F Kefford

8501 Background: GSK436 is a highly potent, selective ATP-competitive BRAF inhibitor. BRF112680, a first in human study, assessed safety, pharmacokinetics, pharmacodynamics, and efficacy. Efficacy of single-agent GSK436 was demonstrated in BRAF V600 mutation-positive (mut+) metastatic melanoma patients (pts), with an unconfirmed response rate (RR) of 77% in V600E mut+ pts and 44% in V600K mut+ ...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2013
Daniel D Buchanan Aung K Win Michael D Walsh Rhiannon J Walters Mark Clendenning Belinda Nagler Sally-Ann Pearson Finlay A Macrae Susan Parry Julie Arnold Ingrid Winship Graham G Giles Noralane M Lindor John D Potter John L Hopper Christophe Rosty Joanne P Young Mark A Jenkins

BACKGROUND Previous reports suggest that relatives of colorectal cancer (CRC)-affected probands carrying the BRAF p.V600E mutation are at an increased risk of CRC and extracolonic cancers (ECC). In this study, we estimated the association between a family history of either CRC or ECC and risk of CRC with a BRAF p.V600E mutation. METHODS Population-based CRC cases (probands, ages 18-59 years a...

2016
Baltruškevičienė Edita Mickys Ugnius Žvirblis Tadas Stulpinas Rokas Pipirienė Želvienė Teresė Aleknavičius Eduardas

Background. KRAS mutation is an important predictive and prognostic factor for patients receiving anti-EGFR therapy. An expanded KRAS, NRAS, BRAF, PIK3CA mutation analysis provides additional prognostic information, but its role in predicting bevacizumab efficacy is unclear. The aim of our study was to evaluate the incidence of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal canc...

Journal: :Head & neck 2015
Sebastian M Jara Ramneesh Bhatnagar Hui Guan Christopher D Gocke Syed Z Ali Ralph P Tufano

BACKGROUND The purpose of this study was to evaluate the diagnostic utility of BRAF mutation testing on thyroid nodules "suspicious for papillary thyroid carcinoma" (PTC) cytology. METHODS A chart review of patients with fine-needle aspiration (FNA) results "suspicious for PTC" with subsequent thyroidectomy was performed. Corresponding archived FNA slides underwent BRAF mutation testing. RE...

Journal: :VNU Journal of Science: Medical and Pharmaceutical Sciences 2023

This study aims to evaluate the mutation status of KRAS, BRAF, NRAS, PIK3CA, and AKT analyze association gene mutations with clinicopathological characteristics colorectal cancer. 151 cancer patients were diagnosed at Pathology Molecular Biology Center in National Cancer Hospital K. The research was conducted as a cross-sectional using methods such genomic DNA extraction; analysis by Real-time ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید